Type II phospholipase A2 and its use in killing Gram-positive bacteria
AssigneeNew York University
InventorsYvette Weinrauch, Peter Elsbach, Jerrold Weiss
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for killing Gram-positive bacterial infections in animals comprising exposing the bacteria to Gram-positive bactericidal-effective amounts of Type II phospholipase A2. The Type II phospholipase A2 can be isolated from mammalian species including humans, cows, rabbits, rats, mice, cats, and dogs. Type II phospholipase A2 is effective in treating infections in mammals, including humans, caused by gram-positive bacteria such as Staphylococcus aureus. Also disclosed are pharmaceutical formulations for use in the methods.
Claims7
A pharmaceutical formulation comprising
- a mammalian Type II phospholipase A2, a pharmaceutically acceptable carrier or diluent, and a member selected from the group consisting of excipients preservatives and stabilizers.
A dosage unit for treating a mammal suffering from an infection caused by a Gram-positive bacteria comprising
- a mammalian Type II phospholipase A2;
- an excipient;
- and
- a physiologically acceptable carrier or diluent.
A pharmaceutical formulation comprising
- a mammalian Type II phospholipase A2;
- a β-lactam antibotic and a pharmaceutically acceptable carrier or diluent.
Dependencies are inferred from the claim text.